UNSPSC 51263135: Tertatolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H25NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9ZO341YQXP, chemically known as 2-propanol, 1-((3,4-dihydro-2h-1-benzothiopyran-8-yl)oxy)-3-((1,1-dimethylethyl)amino)- but generally known as tertatolol, which bears US NIH Compound Identifier 36920. European Medicines Agency schedules Tertatolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10933MIG.

UNSPSC 51263135 Tertatolol, a Commodity code, appears in state and local procurement activity centered on naloxone and pharmaceutical-related acquisitions, though recent opportunities show limited direct alignment with the code's nominal scope. Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB posted June 30, 2026, with a due date of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026, exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. Both opportunities reflect state and local interest in pharmaceutical procurement and supply chain innovation, though neither solicitation explicitly references tertatolol or beta-blocker products as primary procurement targets.

Activity under this code remains sparse and geographically limited to recent postings in Florida and Texas. The Seminole County IFB represents transactional procurement for emergency pharmaceutical supplies with quarterly delivery requirements, fixed-fee pricing, and standard insurance and compliance requirements including E-Verify and drug-free workplace certification. The Texas HHS RFI is exploratory, designed to gather market intelligence on direct contracting models and vendor capabilities rather than commit to specific products or pricing. Set-asides and disadvantaged-enterprise designations do not appear in either opportunity. The mismatch between the code's tertatolol designation and the actual pharmaceutical products being solicited suggests that state and local procurement databases may tag pharmaceutical and health-related acquisitions to this code inconsistently, making it difficult to characterize sustained demand for products under this specific commodity classification.